# Bortezomib in Combination With Ibrutinib in Ibrutinib Relapsed Mantle Cell Lymphoma

> **NCT03617484** · PHASE2 · WITHDRAWN · sponsor: **University of Michigan Rogel Cancer Center**

## Conditions studied

- Mantle Cell Lymphoma

## Interventions

- **DRUG:** Bortezomib
- **DRUG:** Ibrutinib

## Key facts

- **NCT ID:** NCT03617484
- **Lead sponsor:** University of Michigan Rogel Cancer Center
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2020-07
- **Primary completion:** 2023-01
- **Final completion:** 2030-07
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** Enrollment and/or interactions/interventions temporarily paused due to COVID-19 and expected to resume in the future. This is not a suspension of IRB approval.
- **Last updated:** 2020-06-22


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03617484

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03617484, "Bortezomib in Combination With Ibrutinib in Ibrutinib Relapsed Mantle Cell Lymphoma". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT03617484. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*